![](https://endpts.com/wp-content/uploads/2023/08/GettyImages-1245615126-scaled.jpg)
Jason Kelly, Ginkgo Bioworks CEO (Adam Glanzman/Bloomberg via Getty Images)
Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs
In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new RNA drugs, the Boston-based synthetic biology startup exclusively told …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.